Though we found the association between NMGs signature and tumor microenvironment or driver gene alterations (especially EGFR), which may affect the decision-making for clinical management for LUAD patients, the validation of the indication that the difference in the efficacy of immune checkpoint inhibitor and targeted therapy on patients with high- or low-risk signature is worthy to explore in further study, as well as the underlying regulatory mechanism in vivo or in vitro. The gene discussed is EGFR; the disease is neoplasm.